Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22783579 | 0.84 | CYP2C9 (0.47) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL24533356 | 0.82 | CYP2C9 (0.46) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL16618521 | 0.78 | CYP3A4 (0.61) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL17953054 | 0.78 | CYP3A4 (0.61) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL22783548 | 0.76 | CYP3A4 (0.48) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL25112185 | 0.75 | CYP3A4 (0.48) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL25112258 | 0.73 | CYP2D6 (0.31) | CYP2D6ALDH1A1 | |
| SCHEMBL6435944 | 0.71 | CYP2C9 (0.69) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL25112741 | 0.70 | CYP2C9 (0.47) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 | |
| SCHEMBL10095036 | 0.68 | CLK1 (0.37) | CYP2C9CYP2D6CYP3A4CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | CIDARA THERAPEUTICS, INC. | 2023-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079107-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | FCGR3B, FCGR1A, FCGR2A | CYP2C9 1646/4885CYP2D6 1815/4885CYP3A4 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.